S&P Futures
3,218.75-12.50(-0.39%)Dow Futures
26,593.00-92.00(-0.34%)Nasdaq Futures
10,754.00-75.00(-0.69%)
Palatin Technologies, Inc. (PTN)
Chart Events
Performance Outlook
| Previous Close | 0.5076 |
| Open | 0.5130 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1800 |
| Day's Range | 0.4850 - 0.5130 |
| 52 Week Range | 0.3600 - 0.9500 |
| Volume | 1,382,446 |
| Avg. Volume | 2,011,148 |
| Market Cap | 112.107M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | 3.24 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
Palatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced today that it will be presenting at the H.C. Wainwright & Co., 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 4:00 p.m. EDT. The conference will be held virtually.
- PR Newswire
Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth Conference
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity's 40th Annual Growth Conference in a Fireside Chat today at 10:30 am ET. The conference was held virtually.
- PR Newswire
Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced reinitiation of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease (DED).
